We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Supernus Pharmaceuticals Inc | NASDAQ:SUPN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.76 | 2.59% | 30.07 | 28.00 | 40.00 | 30.19 | 29.17 | 29.46 | 330,640 | 01:00:00 |
Delaware
|
001-35518 | 20-2590184 | |||||||||
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|||||||||
9715 Key West Avenue |
Rockville
|
MD
|
20850
|
||||||||
(Address of Principal Executive Offices)
|
(Zip Code)
|
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Common Stock, $0.001 par value per share | SUPN | The Nasdaq Global Market |
SUPERNUS PHARMACEUTICALS, INC. | ||||||||
DATED: May 5, 2021 | By: | /s/ James P. Kelly | ||||||
James P. Kelly | ||||||||
Executive Vice-President and Chief Financial Officer |
1 Year Supernus Pharmaceuticals Chart |
1 Month Supernus Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions